August 2025 in “Ophthalmic Plastic and Reconstructive Surgery” In this case report, a 4-year-old with neurofibromatosis type 1 experienced significant reduction in an inoperable periorbital plexiform neurofibroma and visual improvement following treatment with selumetinib.
87 citations
,
December 2015 in “Cochrane library” This review observed limited evidence of clinically significant benefits from treatments for acute central serous chorioretinopathy, which often resolves spontaneously, but identified PDT and micropulse laser as the most promising for further trials.
6 citations
,
January 2019 in “Dermatology Research and Practice” This study found that ocular and mucocutaneous sequelae are common in SJS/TEN survivors, with exposure to sulfadoxine and severe acute ocular involvement identified as significant risk factors for ocular sequelae.
3 citations
,
November 2021 in “Frontiers in medicine” In this retrospective study at Hiroshima University, methotrexate effectively controlled ocular inflammation in Japanese patients with non-infectious uveitis over 6 to 24 months, but a high incidence of adverse effects indicates careful monitoring and dose adjustments are important.
14 citations
,
September 2019 in “Eye” This review discusses the evidence for using oral medications to treat central serous chorioretinopathy, highlighting eplerenone as having the most support despite a lack of robust efficacy across studies.
